Evidence map›Paper›PMID 40754868›Full record

ReviewCurrent neuropharmacology2026

MicroRNAs as Potential Biomarkers and Therapeutic Targets in Ischemic Stroke from the Perspective of Inflammation.

Nai-He Chen, Jia-Xin Ren, Guang-Jian Li, Xin Sun

Abstract readReview
In one paragraph

Review in Current neuropharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nai-He ChenDepartment of Neurology, The First Hospital of Jilin University, Changchun, 130021, China.ORCID 0000-0001-7228-1620
Jia-Xin RenDepartment of Neurology, The First Hospital of Jilin University, Changchun, 130021, China.
Guang-Jian LiDepartment of Neurology, The First Hospital of Jilin University, Changchun, 130021, China.ORCID 0009-0006-2381-3081
Xin SunDepartment of Neurology, The First Hospital of Jilin University, Changchun, 130021, China.

Funding

National Key R&D Program of China 2022YFC2504904Science and Technology Department of Jilin Province YDZJ202301ZYTS520
6 · The paper itself

Abstract

Ischemic stroke, triggered by the interruption of cerebral blood flow, initiates a complex inflammatory process involving both brain-resident and peripheral immune cells. Microglia, the primary brain-resident immune cells of high heterogeneity, regulate central nervous system inflammation upon activation. Activated microglia are commonly classified into two predominant phenotypes (pro-inflammatory M1 and anti-inflammatory M2), which exert dual effects through the secretion of distinct cytokine profiles. Peripheral immune cells, including monocytes, macrophages, and neutrophils, contribute to stroke pathogenesis and progression via diverse inflammatory mechanisms. Multiple microRNAs regulate the inflammatory dynamics of ischemic stroke across all phases by modulating both brain-resident and peripheral immune cells. MicroRNAs play a pivotal role in the activation and polarization of microglia, as well as cytokine release. Furthermore, microRNAs modulate the activation and extravasation processes of peripheral leukocytes by enhancing or attenuating signaling pathways. These mechanisms suggest that microRNA alterations could be biomarkers for predicting, diagnosing, and prognosticating ischemic stroke. Additionally, microRNA modulation offers potential as a therapeutic strategy for the treatment of ischemic stroke.

Indexed as

InflammationIschemic StrokeMicroRNAsAnimalsBiomarkersHumansMicrogliaBiomarkersMicroRNAsimmune cellsinflammationIschemic strokemicroglia.microRNAsperipheral immune cells

Identifiers

PMID40754868
PMCPMC13084767

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.